Tanasi Review: A Patent Is Not Evidence of Effect
Tanasi sells CBD products built around a proprietary ratio of CBD to CBDA — cannabidiolic acid, the raw acidic form of the cannabinoid in the living plant — developed from university-affiliated research and covered by patent. That positioning is more specific than most of this category, which makes it worth examining precisely rather than dismissing. The distinction that matters is between what a patent establishes and what a clinical trial establishes.
Verified August 25, 2026. Tanasi sells CBD, not medicine. CBD is not a weight-loss product. For weight-loss medication see our GLP-1 provider rankings.
Affiliate disclosure: Rx Saver Hub earns a commission if you sign up through links on this page. It does not change what we write — see our disclosure policy.
Verdict: A more substantive claim than most of the category makes, and still not the claim buyers hear. CBDA is genuinely a distinct molecule rather than marketing language — it is the acidic precursor that converts to CBD when heated, and preclinical work has explored differences between the two. A patent, however, establishes that something is novel, useful and non-obvious. It does not establish that it works in humans, because patent examiners do not review clinical efficacy. University affiliation likewise describes where research happened rather than what it concluded. Ask for the human trials, and read what they measured.
What Tanasi Costs
Products built around the patented CBD-to-CBDA ratio.
| Plan | What you get | Listed | Real cost |
|---|---|---|---|
| Tinctures | CBD and CBDA ratio | Varies | The core positioning |
| Capsules and topicals | Same formulation approach | Varies | Delivery differs |
| The patent | Novelty, utility, non-obviousness | N/A | Not an efficacy finding |
| Human trials | What would establish effect | Ask for them | The question to put |
What a patent establishes, and what it does not
A US patent requires that an invention be novel, useful and non-obvious. The utility bar is low and is not a clinical efficacy standard — patent examiners do not assess whether a formulation improves a health outcome in humans, and thousands of patents exist for things that were never shown to work. Similarly, developed from university research describes the setting rather than the finding. The questions worth asking any brand making this kind of claim are specific: which human trials, how many participants, what outcome was measured, was it placebo-controlled, and is it published somewhere you can read it. A brand with strong answers benefits from the question. That is exactly why it is worth asking.
Divide price by total milligrams of active cannabinoid, as with any product in this category.
What CBDA actually is
In the living hemp plant, cannabinoids exist mainly in acidic forms — CBDA and THCA. Heat converts them to CBD and THC through decarboxylation, which is what happens during most extraction and processing.
So a product retaining CBDA has been processed differently, and that is a real formulation difference rather than a label claim. Preclinical work has examined CBDA's distinct receptor activity and there is interest in its absorption characteristics.
Preclinical means cells and animals. The translation rate from preclinical promise to human benefit is low across all of medicine, and cannabinoid research is no exception.
None of that makes the claim false. It makes it unproven in humans, which is a different and more accurate description than the marketing conveys.
How to evaluate any science-forward supplement claim
Ask for the human trials by name, then check three things: how many people, what was actually measured, and whether there was a placebo control. Small uncontrolled studies of subjective outcomes are the weakest form of evidence and the most commonly cited.
Check whether the research was published in a peer-reviewed journal you can find, or exists only as a company summary. That difference is substantial.
Check who funded it. Industry funding does not invalidate research, but it is context, and independent replication is what settles a question.
Apply the same standard to every brand. This site applies it to prescription medication too, which is why the GLP-1 pages cite the trials by outcome rather than by press release.
The category basics still apply
Ask for a current batch-matched certificate of analysis covering potency, pesticides, heavy metals, residual solvents and microbials. Testing claims mean what the document says.
CBD inhibits cytochrome P450 liver enzymes, which metabolise a long list of prescription drugs. A pharmacist can check your medication list in minutes.
Products retaining full-plant material may contain trace THC, which can produce a positive workplace drug test with regular use.
There is no evidence CBD or CBDA affects weight, and this site would not suggest buying either for that.
Pros and Cons
Strengths
- CBDA is a genuinely distinct molecule rather than marketing language
- More specific formulation positioning than most of the category
- Research-linked development gives something concrete to interrogate
Drawbacks
- A patent establishes novelty, not clinical efficacy
- Preclinical interest in CBDA has not been established as human benefit
- University affiliation describes setting rather than finding
- Inhibits liver enzymes that metabolise many prescription drugs
- No relevance to weight; not FDA-reviewed for effectiveness
Who Should Pick It — and Who Shouldn't
Good fit
Someone curious about CBDA specifically who understands the evidence is preclinical and who asks for the human trials before assuming.
Look elsewhere
Anyone reading a patent as proof of effect, and anyone expecting a cannabinoid product to affect weight.
Frequently Asked Questions
Does a patent mean a supplement works?
No. A patent requires novelty, utility and non-obviousness — the utility bar is low and examiners do not assess clinical efficacy in humans. Thousands of patents exist for things never shown to work.
What is CBDA?
Cannabidiolic acid, the acidic form of the cannabinoid present in the living plant, which converts to CBD when heated. A product retaining it has been processed differently, which is a real formulation difference. Human evidence for distinct benefit is limited.
How should I evaluate a science-backed supplement claim?
Ask which human trials, how many participants, what outcome was measured, whether it was placebo-controlled, and whether it is published where you can read it. A brand with strong answers benefits from the question.
Does CBDA help with weight loss?
No. There is no evidence any cannabinoid product produces weight loss.
Considering Tanasi?
Ask for the human trials, not the patent number. Any brand with good answers is happy to give them.
More Reviews Like This
Other brands we have reviewed in the same category.
Product positioning read from tanasi.com and published sources on August 25, 2026; the site blocks automated access, so details were corroborated from published sources rather than scraped. These statements have not been evaluated by the Food and Drug Administration. Rx Saver Hub earns a commission on purchases made through links on this page.